NPCE at a glance
NeuroPace Inc (NPCE, SEC CIK 1528287) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), NeuroPace Inc (NPCE) reported revenue of $100.0 million (up 25.1% from FY2024) and a net loss of $21.5 million. Diluted EPS was -$0.66.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding NeuroPace Inc (NPCE) shares worth $117.7 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Huennekens R Scott on November 18, 2026 of 12,500 shares at $8.29 per share.
- In the last 90 days, NPCE insiders reported 3 open-market purchases ($302K) and 0 open-market sales ($0) on Form 4, a net purchase of $302K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $100.0M
- +25.1% vs prior year
- Insiders · 90 days
- 3 buys · 0 sells
- Net +$302K
- 13F holders
- 22 funds
- $117.7M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $23.1M, down 1% YoY from $23.4M, driven by $0.6M lower service revenue
- Gross margin 84.3% vs 82.1% YoY, reflecting improved labor absorption and standard-cost benefits
- RNS System revenue up $0.3M, offsetting service-revenue decline; DIXI sales discontinued
- Cash, equivalents and short-term investments $49.2M, with $59.2M outstanding debt at September 30
- Operating cash flow use $12.6M vs $11.5M YoY; continued losses and negative cash flows expected near term
Risk Factors
- Newly added QMSR risk: QSR superseded on February 2, 2026, raising compliance requirements for the Mountain View manufacturing facility
- Most materially updated regulatory risk: FDA staffing cuts and leadership changes could delay expanded-label reviews for IGE and ages 12 to 17
- Healthcare reform risk: OBBBA expected to reduce Medicaid spending and enrollment, potentially shrinking coverage for RNS procedures
- Operational risk: single-source suppliers include Micro Systems Technologies and Integer for printed circuit assemblies and batteries
- Margin risk: changing tariff framework could weaken RNS gross margins and revenue projections despite limited non-U.S. supply-chain activity
AI summary of the NPCE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Press release covers NeuroPace’s financial results for the quarter ended September 30, 2026
- Investors should review Exhibit 99.1 for revenue, profitability, cash flow and management commentary
Item EX-99.1: Item EX-99.1
- Q3 revenue $23.1M, down 1.1% YoY, with RNS revenue $22.9M, up 1.4%, signaling stalled commercial momentum
- GAAP net loss narrowed to $3.3M from $4.9M, while Adjusted EBITDA improved to $0.4M from negative $1.3M
Item 2.02: Results of Operations and Financial Condition
- Press release announces NeuroPace’s financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the detailed quarterly financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $22.8M, up 17%; RNS revenue $22.5M, up 21.3%, signaling continued adoption in focal epilepsy
- Net loss narrowed to $6.2M from $10.0M; Adjusted EBITDA loss improved to $2.8M from $4.9M
Item EX-99.1: Item EX-99.1
- FDA found the IGE PMA supplement not approvable in its current form, delaying potential RNS indication expansion
- NeuroPace plans a Submission Issue Request and additional NAUTILUS clinical evidence to address FDA questions
Item 7.01: Regulation FD Disclosure
- FDA found RNS System indication expansion not approvable in current form
- Requested additional clinical evidence for antiseizure medication-resistant IGE with GTC seizures
AI summaries of NPCE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for NPCE
Don't miss the next NPCE filing
- Alerts as it files. A push when NPCE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NPCE, by share count.
- Ask anything. An AI agent that reads every NPCE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Huennekens R Scott | Buy | Nov 18, 2026 | 12,500 | $8.29 |
| Becker Joel | Buy | Nov 17, 2026 | 11,891 | $8.35 |
| Williams Patrick F. | Buy | Nov 17, 2026 | 11,891 | $8.34 |
| Morrell Martha | F | Sep 24, 2026 | 335 | $13.97 |
| Williams Patrick F. | F | Sep 20, 2026 | 1,162 | $14.28 |
| Becker Joel | F | Sep 3, 2026 | 1,310 | $14.75 |
| Morrell Martha | F | Aug 27, 2026 | 358 | $14.13 |
| Becker Joel | F | Aug 27, 2026 | 1,126 | $14.13 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $79.9M | $100.0M |
| Gross Profit | - | $59.1M | $77.2M |
| Operating Income | - | -$21.7M | -$16.3M |
| Net Income | - | -$27.1M | -$21.5M |
| Gross Margin | - | 73.9% | 77.2% |
| Op. Margin | - | -27.1% | -16.3% |
| Net Margin | - | -34.0% | -21.5% |
| Balance Sheet | |||
| Total Assets | $107.7M | $94.6M | $105.6M |
| Equity | $20.7M | $8.0M | $19.0M |
| ROE | - | -338.7% | -112.8% |
| Per Share | |||
| EPS | - | $-0.93 | $-0.66 |
| Cash Flow | |||
| Operating CF | - | -$17.9M | -$11.0M |
| CapEx | - | $306K | $332K |
Source: XBRL data in NeuroPace Inc (NPCE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate NPCE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $117.7M |
| Q2 2026 | 22 | $141.8M |
| Q1 2026 | 22 | $110.4M |
| Q4 2025 | 19 | $137.0M |
| Q3 2025 | 17 | $84.8M |
| Q2 2025 | 20 | $89.0M |
| Q1 2025 | 16 | $63.7M |
| Q4 2024 | 11 | $27.7M |
- Bank of America Corp+159.7K (+789%)
- Citadel Advisors LLC+118.4K (+92%)
- D.E. Shaw & Co+102.2K (+63%)
- Millennium Management+20.5K (+67%)
- State Street Corp+16.5K (+3%)
- Morgan Stanley−85.5K (-3%)
- Renaissance Technologies LLC−68.0K (-61%)
- JPMorgan Chase & Co−19.1K (-11%)
- Wells Fargo & Co−16.1K (-59%)
- Two Sigma Investments−15.5K (-51%)
- U.S. Bancorp+74
- FMR LLC (Fidelity)−554.8K
Source: 13F-HR filings on SEC EDGAR (aggregated from 149 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NPCE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 4 | Nov 17, 2026 | - | - | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 21, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 4 | Jun 25, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 4, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
NPCE SEC filings: frequently asked questions
Are NPCE insiders buying or selling?
In the last 90 days, NeuroPace Inc (NPCE) officers, directors and 10% owners reported 3 open-market purchases worth $302,103 by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold NPCE stock?
As of September 30, 2026, the largest NeuroPace Inc (NPCE) holders among the 13F filers tracked by SignalX were Morgan Stanley ($35.3 million), BlackRock ($34.0 million), Vanguard Capital Management LLC ($17.0 million), State Street Corp ($7.8 million), D.E. Shaw & Co ($3.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was NPCE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), NeuroPace Inc (NPCE) reported revenue of $100.0 million (up 25.1% from FY2024) and a net loss of $21.5 million. Diluted EPS was -$0.66. The figures come from the XBRL data in the 10-K.
What did NPCE report in its latest 8-K?
NeuroPace Inc (NPCE) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release covers NeuroPace’s financial results for the quarter ended September 30, 2026.
What are the latest NPCE SEC filings?
NeuroPace Inc (NPCE) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 18, 2026.
What is NPCE's SEC CIK number?
NeuroPace Inc (NPCE)'s SEC Central Index Key (CIK) is 1528287. EDGAR lists every NPCE filing under that number.
Ask anything about NPCE
The research agent reads NPCE's filings, financials, insider trades and 13F holders, then answers with sources.